Responses
Late-breaking abstracts
Clinical trials in-progress
804 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.
